- Title: Subtitle
- A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients
- Creators
- Carlyn Rose Tan - Memorial Sloan Kettering Cancer CenterNoel Estrada-Merly - Medical College of WisconsinHeather Landau - Memorial Sloan Kettering Cancer CenterLazaros Lekakis - University of MiamiRahul Banerjee - University of California, San FranciscoHira Mian - McMaster UniversitySaad Z. Usmani - Levine Cancer InstituteAmr Hanbali - King Faisal Specialist Hospital & Research CentreHillard M. Lazarus - University Hospitals of ClevelandRobert A. Kyle - Mayo ClinicBhagirathbhai Dholaria - Vanderbilt University Medical CenterSusan Bal - University of Alabama at BirminghamChristopher Strouse - University of IowaHemant S. Murthy - Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USABaldeep Wirk - Pennsylvania State UniversityTaiga Nishihori - Moffitt Cancer CenterShaji Kumar - Mayo Clinic, Rochester, Rochester, MN, USA.Nina Shah - University of California, San FranciscoMuzaffar Qazilbash - The University of Texas MD Anderson Cancer CenterAnita D'Souza - Medical College of Wisconsin
- Resource Type
- Letter/Communication
- Publication Details
- Bone marrow transplantation (Basingstoke), Vol.57(2), pp.295-298
- DOI
- 10.1038/s41409-021-01527-z
- PMID
- 34802047
- PMCID
- PMC8825695
- NLM abbreviation
- Bone Marrow Transplant
- ISSN
- 0268-3369
- eISSN
- 1476-5365
- Publisher
- Springer Nature
- Number of pages
- 4
- Grant note
- MorphoSys Bristol Myers Squibb Co.; Bristol-Myers Squibb Seagen, Inc. Pfizer, Inc.; Pfizer Sanofi Genzyme; Sanofi-Aventis; Genzyme Corporation Jazz Pharmaceuticals, Inc.; Jazz Pharmaceuticals U24CA076518 / Public Health Service from the National Institute of Allergy and Infectious Diseases (NIAID); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID) Bluebird Bio, Inc. Omeros Corporation Magenta Therapeutics Jasper Therapeutics Orca Biosystems, Inc. Millennium, the Takeda Oncology Co. Daiichi Sankyo Co., Ltd.; Daiichi Sankyo Company Limited ExcellThera Medac GmbH Miltenyi Biotec, Inc. Takeda Pharmaceuticals; Takeda Pharmaceutical Company Ltd Amgen, Inc.; Amgen Karyopharm Therapeutics Pharmacyclics, LLC Vertex; Vertex Pharmaceuticals National Marrow Donor Program CSL Behring N00014-20-1-2705; N00014-20-1-2832 / Office of Naval Research Novartis Pharmaceuticals Corporation; Novartis Tscan Medical College of Wisconsin; General Electric Genentech Inc; Roche Holding; Genentech Gamida-Cell, Ltd. Allovir, Inc. U24CA076518 / Public Health Service from the National Heart, Lung and Blood Institute (NHLBI) Legend Biotech Adienne SA AbbVie Vor Biopharma Adaptive Biotechnologies Corporation Merck Co.; Merck & Company Kyowa Kirin Stemcyte Xenikos BV Fate Therapeutics Angiocrine Bioscience Kiadis Pharma; Dexcel Pharma Eurofins Viracor U24CA076518 / Public Health Service from the National Cancer Institute (NCI) HHSH250201700006C / Health Resources and Services Administration (HRSA); United States Department of Health & Human Services; United States Health Resources & Service Administration (HRSA) Incyte Corporation Astellas Pharma US; Astellas Pharmaceuticals Be the Match Foundation CytoSen Therapeutics, Inc. Kite, a Gilead Company Janssen/Johnson Johnson; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc Oncoimmune, Inc. GlaxoSmithKline Actinium Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Ltd
- Language
- English
- Date published
- 11/20/2021
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359698402771
Letter/Communication
A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients
Bone marrow transplantation (Basingstoke), Vol.57(2), pp.295-298
11/20/2021
DOI: 10.1038/s41409-021-01527-z
PMCID: PMC8825695
PMID: 34802047
Abstract
Details
Metrics
20 Record Views